Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cephalexin + clindamycin is a combination of two antibiotics used together to treat bacterial infections. Cephalexin is a first-generation cephalosporin antibiotic that works by inhibiting bacterial cell wall synthesis, leading to cell lysis and death. It is primarily effective against gram-positive bacteria. Clindamycin is a lincosamide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, making it effective against anaerobic bacteria and certain gram-positive organisms, including some strains resistant to other antibiotics. This combination may be considered in cases where mixed aerobic and anaerobic infections are suspected or when broader coverage is needed due to resistance patterns[2][4][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on cephalexin + clindamycin.